Compare Adaptive Biotechnologies Corp (ADPT) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Adaptive Biotechnologies Corp trades at $24.9 (market cap $4.04B), while iShares 10 20 Year Treasury Bond ETF trades at $96.59. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | TLH | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Fixed Income |
52-Week High | $25.45 | $105.36 |
52-Week Low | $12.30 | $96.39 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
TLH trades at $96.62 with minimal daily movement (+0.24%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock faces resistance at $97 and support at $96. Recent dividend payments of $0.38, $0.36, and $0.41 in mid-2026 indicate ongoing shareholder returns despite the challenging technical backdrop.
The outlook remains cautious with bearish technical signals dominating. Key resistance at $97 must be breached for bullish momentum. Dividend consistency provides some stability, but the lack of fundamental data and weak technical structure suggests limited near-term upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
